Sākums › Multiplā mieloma › Masačūsetsa › Boston
Multiplā mieloma klīniskie pētījumi Boston, MA
42 pētījumi par Multiplā mieloma meklē dalībniekus vietās Boston apkaimē (aptuveni 30 jūdžu rādiusā). Atveriet pētījumu, lai redzētu, kas var piedalīties un kā sazināties ar pētījuma komandu.
Oficiālais pētījuma teksts (angļu valodā)
Meklējat dalībniekus pētījumam? Izceliet to šīs lapas augšdaļā — $99 par 30 dienām →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Notiek dalībnieku piesaiste3. fāze
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste3. fāze
- Tufts Medical Center, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste3. fāze
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Notiek dalībnieku piesaiste3. fāze
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Notiek dalībnieku piesaiste4. fāze
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Mass General Brigham, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Beth Israel Deaconess Medical Center, Boston
ELISA in Relapsed/Refractory MM
Notiek dalībnieku piesaiste2. fāze
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Notiek dalībnieku piesaiste3. fāze
- Boston Medical Center, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Notiek dalībnieku piesaiste1/2. fāze
- Dana-Farber Cancer Institute /ID# 271846, Boston
Elranatamab in R/R Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Massachusetts General Hospital, Boston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Notiek dalībnieku piesaiste3. fāze
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Notiek dalībnieku piesaiste1/2. fāze
- GSK Investigational Site, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Research Site, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Notiek dalībnieku piesaiste3. fāze
- Tufts Medical Center, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Notiek dalībnieku piesaiste1/2. fāze
- Boston Medical Center, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Notiek dalībnieku piesaiste1. fāze
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Notiek dalībnieku piesaiste1/2. fāze
- Research Site, Boston
- Research Site, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Notiek dalībnieku piesaiste2. fāze
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Notiek dalībnieku piesaiste1/2. fāze
- Dana Farber Cancer Institute, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Notiek dalībnieku piesaiste1. fāze
- Dana Farber/Harvard Cancer Center, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Notiek dalībnieku piesaiste
- Dana-Farber Cancer Institute, Boston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Notiek dalībnieku piesaiste3. fāze
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Dana Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Notiek dalībnieku piesaiste1. fāze
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Notiek dalībnieku piesaiste1. fāze
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Notiek dalībnieku piesaiste
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Notiek dalībnieku piesaiste1. fāze
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Notiek dalībnieku piesaiste1/2. fāze
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1. fāze
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Notiek dalībnieku piesaiste
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Notiek dalībnieku piesaiste2. fāze
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Notiek dalībnieku piesaiste1/2. fāze
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Notiek dalībnieku piesaisteNovērojumu pētījums
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Notiek dalībnieku piesaiste1/2. fāze
- Dana-Farber Cancer Institute, Boston
Multiplā mieloma pētījumi citās pilsētās
- New York City, NY60 pētījumi
- Atlanta, GA41 pētījums
- Houston, TX38 pētījumi
- Durham, NC37 pētījumi
- Nashville, TN32 pētījumi
- Denver, CO27 pētījumi
- Rochester, MN24 pētījumi
- St. Louis, MO24 pētījumi
- Columbus, OH24 pētījumi
- Baldwin Park, CA23 pētījumi
- Chicago, IL22 pētījumi
- Seattle, WA22 pētījumi
Citi pētījumi Boston
- Krūts vēzis111 pētījumi
- Mazšūnu plaušu vēzis90 pētījumi
- Vēzis (visi veidi)86 pētījumi
- Kolorektālais vēzis63 pētījumi
- Metastātisks vēzis63 pētījumi
- Plaušu vēzis62 pētījumi
- Olnīcu vēzis61 pētījums
- Priekšdziedzera vēzis59 pētījumi
- Depresija52 pētījumi
- Endometrija vēzis50 pētījumi
- Sirds mazspēja44 pētījumi
- Akūta mieloīdā leikēmija44 pētījumi
No ClinicalTrials.gov, dati iegūti 2026. gada 5. okt.. Katram pētījumam ir savi dalības nosacījumi; pētījuma komanda nosaka, kas var piedalīties.